Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03909139 · ClinicalTrials.gov registry record
Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear
A clinical trial of Femoroacetabular Impingement and Chondral Defect, sponsored by Massachusetts General Hospital.
- Recruiting
- Registry status
- 400
- Enrollment target
- 1
- Study location
NCT03909139: Recruiting study of Femoroacetabular Impingement and Chondral Defect, sponsored by Massachusetts General Hospital.
NCT03909139 is a study of Femoroacetabular Impingement and Chondral Defect that is actively recruiting participants, run by Massachusetts General Hospital. The registered enrollment target is 400 participants, below the 1,320-participant average among 8 other Femoroacetabular Impingement trials with a reported enrollment target (70% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03909139, a study of Femoroacetabular Impingement and Chondral Defect, is actively recruiting participants, sponsored by Massachusetts General Hospital.
- RECRUITING
- Registry status
- 400 participants
- Enrollment target
- 1
- Study location
Study Summary
Femoro-acetabular impingement is a well known cause of damage to the acetabular labrum and chondrolabral junction. Additionally, it has been proposed that disruption of hip biomechanics resulting from a labral tear causes a faster progression towards osteoarthritis (OA). This progression has been observed to begin with breakdown of the chondrolabral junction with later development of diffuse osteoarthritis. Use of hip arthroscopy has increased dramatically in recent years to treat symptomatic labral tears and potentially avoid the morbidity and cost associated with hip osteoarthritis. Correction of labral pathology presents a technical challenge and many techniques currently exist. Increased understanding of the structure-functional relationship dictated by labral anatomy has led to the development of methods aimed at restoring functional anatomy by re-establishing the labrum's native position and contour on the rim of the acetabulum. Therefore, akin to repairing a torn meniscus in the knee, restoring the anatomic footprint of a torn labrum will reconstitute normal joint biomechanics. Despite the advances in techniques for labral repair, strategies for mitigating or repairing damage to the chondrolabral junction do not yet exist. This area has been shown to consist of hyaline and fibro cartilage. Many techniques for cartilage repair exist, although most are not feasible due to technical challenges specific to the hip joint. The management of articular cartilage defects is one of the most challenging clinical problems for orthopaedic surgeons. Articular cartilage has a limited intrinsic healing capacity, and pathology frequently results in gradual tissue deterioration. Currently, the standard surgical intervention for end-stage degenerative joint pathology is total joint replacement. Early surgical interventions for symptomatic cartilage lesions including cell based therapies such as autologous chondrocyte implantation (ACI), bone marrow aspirate concentrate (BMAC
Primary Outcome
Full Name of Outcome: International Hip Outcome Tool--33 Questions Purpose: Validated Hip Patient Reported Outcome Measurements (PROMs) to assess the patient's functional outcomes post-surgery. Scale of iHOT-33: Min: 0 Max: 100 No standardized scoring categories (i.e. excellent, good, fair, poor). Higher score indicates better hip functionally. No subscores or subscales
Conditions Studied
Interventions
- BIOLOGICAL BMAC
Study Locations (1)
Massachusetts
- MGH, Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2027-06-30 |
What NCT03909139 shows while recruiting
NCT03909139 is an observational study that tracks outcomes without assigning an intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,320-participant average among 8 other Femoroacetabular Impingement trials with a reported enrollment target (70% lower).
The record links to 5 conditions, with Femoroacetabular Impingement appearing as the primary indexed condition, and to 1 intervention - of which BMAC is the first listed.
NCT03909139 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03909139 about?
NCT03909139 is a clinical study titled "Use of BMAC With Hip Arthroscopy Treatment of FAI and Labral Tear". Femoro-acetabular impingement is a well known cause of damage to the acetabular labrum and chondrolabral junction. Additionally, it has been proposed that disruption of hip biomechanics resulting from a labral tear causes a faster progression towards osteoarthritis (OA). This progression has been ob...
What is the current status of trial NCT03909139?
This trial is currently recruiting. The enrollment target is 400 participants. The study started on 2019-09-06. Estimated completion is 2027-06-30.
What conditions does trial NCT03909139 study?
This clinical trial studies the following conditions: Femoroacetabular Impingement, Chondral Defect, Acetabular Labrum Tear, Bone Marrow Aspirate Concentrate, Mesenchymal Stromal Cell.
What interventions are being tested in trial NCT03909139?
The interventions under investigation include: BMAC (BIOLOGICAL).
Who is sponsoring clinical trial NCT03909139?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03909139 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Femoroacetabular Impingement
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03909139's enrollment target sits among peer trials
400 2nd of 8 the highest of 8 other Femoroacetabular Impingement trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Femoroacetabular Impingement trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Early Feasibility Study of Cartilage Defect Repair
RECRUITING · NA
-
An Evaluation of Hip Preservation Outcomes
RECRUITING
-
Effect of PRP, PPP, & BMAC on Functional Outcomes Following Hip Arthroscopy for Acetabular Labral Pathologies
RECRUITING · Phase 3
-
Knotless Implants As an Alternative for Capsular Closure in Primary Hip Arthroscopy: a Prospective, Multi-Center Study
RECRUITING · Phase 4
-
SCP Hip Outcomes Study
ACTIVE NOT RECRUITING
-
Cam Decompression Utilizing the Stryker Hip-Check Software Platform
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI